Literature DB >> 2049247

Ethnic differences in the pharmacokinetics of oral nifedipine.

C H Ahsan1, A G Renwick, B Macklin, V F Challenor, D G Waller, C F George.   

Abstract

1. The pharmacokinetics of a single oral dose of 20 mg nifedipine, given as capsules, has been compared in five South Asian volunteers with data for 27 Caucasian volunteers. 2. The area under the plasma concentration-time curve (AUC) of nifedipine was three fold higher in South Asians (989 +/- 166 ng ml-1 h) than in Caucasians (323 +/- 116 ng ml-1 h). 3. The ratio of the AUC of nifedipine to that of the nitropyridine analogue, which is formed largely as a first pass metabolite, was significantly higher in South Asians (4.6 +/- 1.9) than in Caucasians (2.3 +/- 1.1) indicating a lower first pass metabolism in South Asians. 4. The terminal half-lives of nifedipine and the nitropyridine metabolite were significantly greater in South Asians than in Caucasians. 5. Consumption of a spicy curry diet for 3 days by Caucasians did not significantly affect the pharmacokinetics of a single oral dose of nifedipine. 6. The treatment of patients of South Asian origin with nifedipine should be initiated with lower doses than would be given to Caucasians.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2049247      PMCID: PMC1368324          DOI: 10.1111/j.1365-2125.1991.tb05552.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  16 in total

1.  Factors affecting the pharmacokinetics of nifedipine.

Authors:  A G Renwick; J Le Vie; V F Challenor; D G Waller; B Gruchy; C F George
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

2.  [Clinical study on the pharmacokinetics of radioactively labelled 4-(2'-nitrophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylic acid dimethyl ester].

Authors:  F A Horster; B Duhm; W Maul; H Medenwald; K Patzschke; L A Wegner
Journal:  Arzneimittelforschung       Date:  1972-02

3.  The P450 gene superfamily: recommended nomenclature.

Authors:  D W Nebert; M Adesnik; M J Coon; R W Estabrook; F J Gonzalez; F P Guengerich; I C Gunsalus; E F Johnson; B Kemper; W Levin
Journal:  DNA       Date:  1987-02

4.  Protein binding of nifedipine.

Authors:  J Otto; L J Lesko
Journal:  J Pharm Pharmacol       Date:  1986-05       Impact factor: 3.765

5.  Variability in nifedipine pharmacokinetics and dynamics: a new oxidation polymorphism in man.

Authors:  C H Kleinbloesem; P van Brummelen; H Faber; M Danhof; N P Vermeulen; D D Breimer
Journal:  Biochem Pharmacol       Date:  1984-11-15       Impact factor: 5.858

6.  The first pass metabolism of nifedipine in man.

Authors:  D G Waller; A G Renwick; B S Gruchy; C F George
Journal:  Br J Clin Pharmacol       Date:  1984-12       Impact factor: 4.335

7.  Liquid chromatographic determination of nifedipine in plasma and of its main metabolite in urine.

Authors:  C H Kleinbloesem; J Van Harten; P Van Brummelen; D D Breimer
Journal:  J Chromatogr       Date:  1984-06-08

8.  The effects of propranolol or atenolol on the cardiovascular responses to central hypovolaemia in Europeans and Bengalees.

Authors:  M A Rahman; T Bennett
Journal:  Br J Clin Pharmacol       Date:  1990-01       Impact factor: 4.335

9.  Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism.

Authors:  F P Guengerich; M V Martin; P H Beaune; P Kremers; T Wolff; D J Waxman
Journal:  J Biol Chem       Date:  1986-04-15       Impact factor: 5.157

10.  Polymorphism of human cytochrome P-450.

Authors:  F P Guengerich; D R Umbenhauer; P F Churchill; P H Beaune; R Böcker; R G Knodell; M V Martin; R S Lloyd
Journal:  Xenobiotica       Date:  1987-03       Impact factor: 1.908

View more
  11 in total

Review 1.  Cytochrome P450 3A and their regulation.

Authors:  Oliver Burk; Leszek Wojnowski
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-10-21       Impact factor: 3.000

Review 2.  Dietary effects on drug metabolism and transport.

Authors:  Robert Z Harris; Graham R Jang; Shirley Tsunoda
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 3.  Ethnic or racial differences revisited: impact of dosage regimen and dosage form on pharmacokinetics and pharmacodynamics.

Authors:  Mei-Ling Chen
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

Review 4.  Clinical pharmacokinetic considerations in the elderly. An update.

Authors:  M T Kinirons; P Crome
Journal:  Clin Pharmacokinet       Date:  1997-10       Impact factor: 6.447

Review 5.  Interethnic differences in pharmacokinetics of antibacterials.

Authors:  Danny Tsai; Janattul-Ain Jamal; Joshua S Davis; Jeffrey Lipman; Jason A Roberts
Journal:  Clin Pharmacokinet       Date:  2015-03       Impact factor: 6.447

Review 6.  Clinical pharmacokinetics of calcium antagonists. An update.

Authors:  J G Kelly; K O'Malley
Journal:  Clin Pharmacokinet       Date:  1992-06       Impact factor: 6.447

7.  A Physiologically Based Pharmacokinetic Model for Pregnant Women to Predict the Pharmacokinetics of Drugs Metabolized Via Several Enzymatic Pathways.

Authors:  André Dallmann; Ibrahim Ince; Katrin Coboeken; Thomas Eissing; Georg Hempel
Journal:  Clin Pharmacokinet       Date:  2018-06       Impact factor: 6.447

Review 8.  The nifedipine gastrointestinal therapeutic system (GITS). Evaluation of pharmaceutical, pharmacokinetic and pharmacological properties.

Authors:  J S Grundy; R T Foster
Journal:  Clin Pharmacokinet       Date:  1996-01       Impact factor: 6.447

9.  Factors affecting the absolute bioavailability of nifedipine.

Authors:  T J Rashid; U Martin; H Clarke; D G Waller; A G Renwick; C F George
Journal:  Br J Clin Pharmacol       Date:  1995-07       Impact factor: 4.335

10.  The influence of posture on the pharmacokinetics of orally administered nifedipine.

Authors:  A G Renwick; C H Ahsan; V F Challenor; R Daniels; B S Macklin; D G Waller; C F George
Journal:  Br J Clin Pharmacol       Date:  1992-10       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.